Biotech Funding Sequence: What Money Should You Raise First?
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.
A Bootstrap-First Sequence
There is no single financing path for every company, but many early programs benefit from moving from lower-cost, non-dilutive, or strategically aligned capital toward institutional equity as risk falls.
- Founder, friends-and-family, or university translational support for initial formation and proof points
- SBIR/STTR or other federal grants for feasibility and technical development
- Disease-foundation, state, accelerator, or translational grants for targeted validation
- SBIR/STTR Phase II or equivalent scale-up funding for development milestones
- Strategic partnerships, sponsored development, licensing, or corporate collaboration
- Family office, venture capital, or other institutional equity when larger-scale execution is justified
Match Money to Milestone
A grant is attractive because it is non-dilutive, but it may be slow, restricted, and milestone-specific. Strategic capital can validate the market but may come with rights that constrain future partners. Venture capital can move quickly and fund ambitious development, but it costs equity and often governance rights.
Questions to Ask before Every Raise
Financing should be designed around a value inflection point rather than a generic runway target.
- What milestone will this capital achieve?
- What uncertainty will that milestone remove?
- Will achieving it materially improve valuation or partnering leverage?
- Could a less dilutive source fund all or part of it?
- How much runway is required to reach the next financeable event?
BYB Takeaway
Use the least expensive capital that can credibly achieve the next value-creating milestone. Then reconsider the financing strategy with a stronger asset and better information.
Capital should follow the commercialization roadmap—not substitute for one.
